Lidakol antiviral data

LDAKA said further data from its Phase II trial of Lidakol in women with genital herpes showed that the drug caused a significant reduction in the time from beginning of treatment to the first reduction in the severity of pain. Treated patients experienced their first pain reduction in a mean time of less than a day compared to more than two days in placebo patients (p<0.01). ...